Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

37.61 +1.99 (+5.59%)
Streaming Delayed Price Updated: 2:44 PM EDT, May 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
26 27 28 29 30 31 32 33 Next >
Tough Slogging Ahead for Investors, Diversification is Important
Speculative small/mid-cap biotech stocks hit new lows this past week with the XBI at a “triple bottom” about the $84 level only 10 points above the March 2020 lows. 
Via Talk Markets
Intellia Therapeutics Crashes As Patent Decision Clouds CRISPR Gene-Editing Test
Intellia Therapeutics said its gene-editing drug lowered levels of a troublesome protein. 
Via Investor's Business Daily
Peloton Isn’t the ONLY Takeover Target. What Companies Could Be Bought Out in 2022?
Savvy investors can generate lucrative returns by investing in companies that look like a number of prime takeover targets. 
Via InvestorPlace
Why Jim Cramer Believes Sirius XM Is Inexpensive
On CNBC’s "Mad Money Lightning Round," Jim Cramer said CRISPR Therapeutics AG (NASDAQ: 
Via Benzinga
What Are Whales Doing With CRISPR Therapeutics
A whale with a lot of money to spend has taken a noticeably bullish stance on CRISPR Therapeutics. Looking at options history for CRISPR Therapeutics (NASDAQ:CRSP) we detected 15 strange trades. 
Via Benzinga
CRISPR Therapeutics's Return On Capital Employed Insights
Benzinga Pro data, CRISPR Therapeutics (NASDAQ:CRSP) reported Q4 sales of $12.90 million. Earnings fell to a loss of $141.25 million, resulting in a 11.09% decrease from last quarter. 
Via Benzinga
Week In Review: Xbiome Acquires Diabetic Foot Ulcer Therapy In $139 Million Deal
Xbiome, a Shenzhen AI-based microbiome drug development company, in-licensed China rights to an inflammatory disease therapy developed by Aurealis, a Swiss synthetic biology company, in a deal worth up... 
Via Talk Markets
Here's How Much You Would Have Made Owning CRISPR Therapeutics Stock In The Last 5 Years
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 14.31% on an annualized basis. Buying $1,000 In CRSP: 5 years ago, an investor could have... 
Via Benzinga
Stock Market Rebound Fizzles Amid Hawkish Fed; Taiwan Semiconductor Breaks Out, JPMorgan Tumbles: Weekly Review
A rebound from Monday's lows faded, with the key indexes all down for the week. 
Via Investor's Business Daily
The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks
Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year? 
Via Investor's Business Daily
3 Deep Value Moonshots to Ride Out Powell’s Taper Tantrum
These three companies might seem like zombies compared to other investing opportunities, but they'll be robust during the Fed taper. 
Via InvestorPlace
Pfizer Makes Foray Into CRISPR, Inking $1.35 Billion Deal With Beam Therapeutics
The companies hope to cure diseases of the liver, muscle and central nervous system. 
Via Investor's Business Daily
7 Stock Bargains Worth a Look After the Most Recent Pullback
Value investors may choose to buy stocks that are out of favor and from among beaten up stock bargains in a variety of sectors. 
Via InvestorPlace
Top 5 Moonshots for 2022 Countdown: My No. 5 Pick
2021 wasn't the best year for gene-editing stocks, but expect a comeback in 2022. Here's the top gene-editing choice for next year. 
Via InvestorPlace
Biotech Playbook 2021 Part 2: Rotation Rally Brings Relief after FED Pivot
The new aggressive Fed taper combined with a rise in interest rates for 2022 adds a new element of risk to portfolio management. Monetary policy is a headwind for 2022. 
Via Talk Markets
10 Bargain Stocks to Buy After Falling 30% in 2021
If you’re looking for bargain stocks to buy that are down 30% or more in 2021, that’s not an easy task. Here are 10 that fit the bill. 
Via InvestorPlace
Biotech Playbook 2021: No Help From Small Caps In Q4
Mid-cap stock picks have done better today but are way off their 2021 highs. Cryoport and Veracyte are still up and look better technically. Quidel was up 5.48% today on Omicron concerns globally but... 
Via Talk Markets
Adobe Earnings Strangle Trade
Adobe announces earnings this week, and we plan on using an options strategy called a 
Via Talk Markets
CRISPR Therapeutics Is One of Today’s Best Biotech Value Investments
Don't let the downtrend in CRSP stock fool you; the company is still making headway in advancing potentially life-changing therapeutics. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021
Upgrades For CarMax Inc (NYSE: 
Via Benzinga
Why CRISPR Therapeutics Stock Sank 12.5% in November
The gene-editing specialist's share price is now down roughly 54% in 2021. 
Via The Motley Fool
Jim Cramer Shares His Thoughts On Chegg, Bristol-Myers Squibb And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said with Matterport, Inc. (NASDAQ: 
Via Benzinga
Biotech Stocks are Due for a Rally
There are many rebalancing trades left in your stock portfolio but biotech is in the doldrums. 
Via Talk Markets
Do CRISPR Therapeutics and Intellia Face a Big Safety Risk?
CRISPR gene editing is promising, but there's a risk that it can cause unwanted mutations. 
Via The Motley Fool
Better Buy: Vertex Pharmaceuticals vs. CRISPR
The companies are collaborating on a potential blockbuster. 
Via The Motley Fool
Looking for Growth in Small and Mid Cap Life Science Stocks
2021 is an unusual year for biotech with a “blow-off” February high in speculative small caps. 
Via Talk Markets
Being First Is Not Enough For Crispr Therapeutics
CRSP stock is facing competition and meeting skepticism as the company tries to turn CRISPR-CAS9 into profitable drug therapies. 
Via InvestorPlace
Why CRISPR Therapeutics Stock Fell 18.4% in October
The gene-editing specialist's stock is now down roughly 37% year to date. 
Via The Motley Fool
Why Vertex Is Striking Another Gene-Editing Deal With a Company Not Named CRISPR Therapeutics
Vertex plans to develop gene-editing therapies with Mammoth Biosciences. 
Via The Motley Fool
3 Things About CRISPR Therapeutics That Smart Investors Know
The company's value isn't reflected in typical performance metrics. 
Via The Motley Fool
< Previous 1 2
...
26 27 28 29 30 31 32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.